China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced the signing of a licensing agreement with compatriot firm Xiling Lab’s wholly-owned unit Chengdu Kelingyuan Pharmaceutical Co., Ltd. The agreement grants Chengdu Kelingyuan global development and commercialization rights to the anti-HER2 monoclonal antibody (mAb) Cipterbin (inetetamab) for use as an antibody drug conjugate (ADC) component.
Financial Terms
Under the agreement, Sunshine Guojian will receive an upfront payment, R&D milestone payments, and sales milestone payments totaling RMB 1.025 billion (USD 153 million), along with royalties on global sales of Cipterbin-related ADC products. Sunshine Guojian will retain global rights to the drug outside of the ADC program.
Drug Background
Cipterbin, developed as a bio-better version of Roche’s Herceptin (trastuzumab), gained its first market approval in June 2020, becoming the first domestically developed HER2 mAb to do so. The drug was added to China’s National Reimbursement Drug List (NRDL) in December 2020.-Fineline Info & Tech
